Targeted Conditioning of Iomab-B (131I-anti-CD45) Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Relapsed or Refractory Acute Myeloid Leukemia (AML): Preliminary Feasibility and Safety Results from the Prospective, Randomized Phase 3 Sierra Trial
Year: 2018
Type: conference-abstract
Source: Blood
Authors: Edward Agura, Boglarka Gyurkocza, Rajneesh Nath, Mark R. Litzow, Benjamin K. Tomlinson, Sunil Abhyankar, Stuart Seropian, Patrick J. Stiff, Hannah K. Choe, Partow Kebriaei, James M. Foran, George Chen, Moshe Yair Levy, Hillard M Lazarus, Sergio Giralt, Mark S. Berger, Vijay Reddy, John M. Pagel
Institutions: Baylor University Medical Center, Memorial Sloan Kettering Cancer Center, Banner MD Anderson Cancer Center, Mayo Clinic, University Hospitals of Cleveland, University Hospitals Seidman Cancer Center, University of Kansas Medical Center, Yale University, Loyola University Medical Center, Loyola Medicine, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The University of Texas MD Anderson Cancer Center, Mayo Clinic in Florida, Mayo Clinic Comprehensive Cancer Center (Florida), Roswell Park Comprehensive Cancer Center, University Hospitals Cleveland Medical Center, Actinium Pharmaceuticals (United States), Pharmacyclics (United States)
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2899130436